Company intelligence / Profile preview
Path Therapeutics
Calgary, Alberta, Canadapathbio.com ↗
- Ownership
- Private
- Employees
- ~4
- Development stage
- Other
01
Overview
Path Therapeutics is a private Canadian neuroscience biotech developing first-in-class therapies for severe childhood epilepsies and other brain disorders. The company uses its proprietary MitoREAD neurometabolic phenotypic drug discovery platform to identify novel drug targets by measuring restoration of mitochondrial function. Its lead program is a phosphodiesterase 4 allosteric modulator being optimized for Dravet syndrome and refractory epilepsy, with preclinical proof-of-concept reported in mouse models. The company was co-founded by Deborah Kurrasch and Jong Rho and is backed at least in part by early support from Viva Biotech/Viva BioInnovator.
- Therapeutic areas
- Neurology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Viva BiotechViva BioInnovator
Beyond the preview
Go deeper on Path Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Path Therapeutics.